期刊 CAPIRI方案治疗老年转移性结直肠癌一线FOLFOX方案治疗失败患者的临床分析  

Efficacy and safety of CAPIRI in the treatment of elderly patients with primary FOLFOX in the treatment of metastatic colorectal cancer

作  者:李晶晶 廖晓琴 吴继萍[1] 过丽珍 卢根娣[1] 

Li Jingjing;Liao Xiaoqin;Wu Jiping;Guo Lizhen;Lu Gendi(Surgery,Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine,Shanghai,201203,P.R.China)

机构地区:[1]上海中医药大学附属曙光医院胃肠外科,上海201203

出  处:《老年医学与保健》2021年第5期1076-1079,1085,共5页Geriatrics & Health Care

Efficacy and safety of CAPIRI in the treatment of elderly patients with primary FOLFOX in the treatment of metastatic colorectal cancer

基  金:上海护理学会科研项目(2019QN-B03)。

摘  要:目的探讨伊立替康+卡培他滨(CAPIRI)方案治疗老年转移性结直肠癌一线奥沙利铂+甲酰四氢叶酸钙+氟尿嘧啶(FOLFOX)方案治疗失败患者的有效性及安全性。方法收集2018年7月-2020年12月上海中医药大学附属曙光医院确诊并收治的老年转移性结直肠癌一线FOLFOX方案治疗失败患者122例,按照计算机随机分配法分成观察组与对照组,每组61例。对照组患者予以伊立替康+氟尿嘧啶(FOLFIRI)方案治疗,观察组予以CAPIRI方案治疗,2组连续治疗6个月。观察并比较2组临床疗效、不良反应和生存时间;观察并比较2组治疗前后的生活质量量表(SF-36)评分及血清基质金属蛋白酶-2 (MMP-2)、转化生长因子β1 (TGF-β1)、基质金属蛋白酶-9 (MMP-9)水平。结果 2组患者的疾病控制率、客观缓解率、总生存时间及患者无进展生存时间差异均无统计学意义(P> 0.05);治疗前,两组MMP-2、TGF-β1、MMP-9、SF-36评分差异无统计学意义(P> 0.05);治疗后,2组血清MMP-2、MMP-9及TGF-β1水平较同组治疗前下降(P<0.05),观察组血清MMP-2、MMP-9及TGF-β1水平较对照组差异均无统计学意义(P> 0.05);治疗后,2组SF-36评分相较于同组治疗前升高(P<0.05),观察组SF-36评分高于对照组(P<0.05);观察组患者总不良反应发生率较对照组减少(P<0.05)。结论 CAPIRI方案治疗老年转移性结直肠癌一线FOLFOX方案治疗失败患者的有效性及安全性较好,不良反应较少,有助于改善患者生存质量。

Objective Efficacy and safety of Irinotecan+capecitabine(CAPIRI)regimen in the treatment of elderly patients with metastatic colorectal cancer who failed to receive first-line Oxaliplatin+calcium formyltetrahydrofolate+flu-orouracil(FOLFOX)regimen.Methods 122 Elderly Patients with metastatic colorectal cancer who were diagnosed and treated in Shuguang Hospital Affiliated to Shanghai University of traditional Chinese medicine from July 2018 to December 2020 were collected,According to the computer random distribution method,they were divided into observation group and control group,with 61 cases in each group.The control group was treated with irinotecan+fluorouracil(FOLFIRI)regimen,the observation group was treated with capiri regimen,and the two groups were treated for 6 months.The clinical efficacy,adverse reactions and survival time of the two groups were observed and compared;The scores of quality of life scale(SF-36)and the levels of serum matrix metalloproteinase-2(MMP-2),transforming growth factor-β1(TGF-β1)and matrix metalloproteinase-9(MMP-9)were observed and compared between the two groups before and after treatment.Results There was no significant difference in objective remission rate,disease control rate,overall survival time and progression free survival time between the two groups(P>0.05);Before treatment,there was no significant difference in the scores of MMP-2,TGF-β1,MMP-9 and SF-36 between the two groups(P>0.05);After treatment,the serum levels of MMP-2,MMP-9 and TGF-β1 in the two groups were significantly decreased compared with those before treatment(P<0.05),and there was no significant difference between the two groups(P>0.05);After treatment,the SF-36 score of the two groups was significantly higher than that before treatment(P<0.05),and the SF-36 score of the observation group was significantly higher than that of the control group(P<0.05);The total incidence of adverse reactions in the observation group was signifi-cantly lower than that in the control group(P<0.05).Conclusion CAPIRI

关 键 词:老年 转移性结直肠癌 CAPIRI方案 二线治疗 有效性 安全性 

ederly metastatic colorectal cancer CAPIRI scheme second line treatment effectiveness security 

分 类 号:R73[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关文献:

正在载入数据...

北京电子科技职业学院特色库 版权所有 ©2018